PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 24680768-2 2014 An immediate-release oral formulation of tacrolimus has been commercially available since 1994 that is administered orally BID. Tacrolimus 41-51 BH3 interacting domain death agonist Homo sapiens 123-126 24981811-14 2014 Tacrolimus dose was increased to 3 mg bid (9/9/2010), awaiting tacrolimus levels. Tacrolimus 0-10 BH3 interacting domain death agonist Homo sapiens 38-41 24981811-15 2014 Subsequent levels (ng/mL) were 8.6 and 9.5, which made us resume the prior tacrolimus dose (2 mg bid). Tacrolimus 75-85 BH3 interacting domain death agonist Homo sapiens 97-100 26953629-3 2016 A novel once-daily formulation of tacrolimus (LCPT) has demonstrated noninferiority, similar safety, improved bioavailability, a consistent concentration time profile, and less peak and peak-trough fluctuations vs. tacrolimus twice-daily (Tac BID). Tacrolimus 34-44 BH3 interacting domain death agonist Homo sapiens 243-246 23082898-1 2012 OBJECTIVES: The once-daily prolonged-release formulation of tacrolimus (tacrolimus QD) is expected to demonstrate equivalent efficacy and safety to the twice-daily formulation (tacrolimus BID). Tacrolimus 60-70 BH3 interacting domain death agonist Homo sapiens 188-191 23483701-2 2013 The aim of the present study was to evaluate the safety and efficacy of conversion from a tacrolimus (TAC) twice daily (bid) formulation to a once daily (qd) formulation in a large cohort of adult liver transplantation (LT) patients. Tacrolimus 90-100 BH3 interacting domain death agonist Homo sapiens 120-123 23622676-12 2013 CONCLUSION: We observed that in a real-world setting far from LT centers, the switch from BID tacrolimus to QD tacrolimus in stable LT recipients is efficient (safe and effective) to improve quality of medical care, with possibly better IS adherence and improvement of renal function. Tacrolimus 94-104 BH3 interacting domain death agonist Homo sapiens 90-93 23622676-12 2013 CONCLUSION: We observed that in a real-world setting far from LT centers, the switch from BID tacrolimus to QD tacrolimus in stable LT recipients is efficient (safe and effective) to improve quality of medical care, with possibly better IS adherence and improvement of renal function. Tacrolimus 111-121 BH3 interacting domain death agonist Homo sapiens 90-93 23082898-10 2012 CONCLUSIONS: Patients taking tacrolimus QD tended to have lower trough levels and require higher dosages than those taking tacrolimus BID during the early posttransplant period, though the differences decreased with increasing time after transplant. Tacrolimus 123-133 BH3 interacting domain death agonist Homo sapiens 134-137 22249344-12 2012 CONCLUSIONS: The results of this study provide evidence for safe conversion from Tacrolimus BID to QD with appropriate trough concentration monitoring. Tacrolimus 81-91 BH3 interacting domain death agonist Homo sapiens 92-95 22406656-3 2012 In a previous study of the pharmacokinetics (PK) of these formulations, mean systemic exposure [area under the curve from 0 to 24 hours (AUC0-24)] of tacrolimus on day 1 was approximately 30% lower for Tacrolimus QD than for Tacrolimus BID; by day 14, systemic exposure was similar; however, the mean dose of Tacrolimus QD was higher to achieve similar systemic exposure as Tacrolimus BID. Tacrolimus 150-160 BH3 interacting domain death agonist Homo sapiens 236-239 22406656-3 2012 In a previous study of the pharmacokinetics (PK) of these formulations, mean systemic exposure [area under the curve from 0 to 24 hours (AUC0-24)] of tacrolimus on day 1 was approximately 30% lower for Tacrolimus QD than for Tacrolimus BID; by day 14, systemic exposure was similar; however, the mean dose of Tacrolimus QD was higher to achieve similar systemic exposure as Tacrolimus BID. Tacrolimus 150-160 BH3 interacting domain death agonist Homo sapiens 385-388 22406656-3 2012 In a previous study of the pharmacokinetics (PK) of these formulations, mean systemic exposure [area under the curve from 0 to 24 hours (AUC0-24)] of tacrolimus on day 1 was approximately 30% lower for Tacrolimus QD than for Tacrolimus BID; by day 14, systemic exposure was similar; however, the mean dose of Tacrolimus QD was higher to achieve similar systemic exposure as Tacrolimus BID. Tacrolimus 202-212 BH3 interacting domain death agonist Homo sapiens 236-239 22406656-3 2012 In a previous study of the pharmacokinetics (PK) of these formulations, mean systemic exposure [area under the curve from 0 to 24 hours (AUC0-24)] of tacrolimus on day 1 was approximately 30% lower for Tacrolimus QD than for Tacrolimus BID; by day 14, systemic exposure was similar; however, the mean dose of Tacrolimus QD was higher to achieve similar systemic exposure as Tacrolimus BID. Tacrolimus 202-212 BH3 interacting domain death agonist Homo sapiens 385-388 22406656-7 2012 RESULTS: Mean AUC0-24 of tacrolimus on day 1 was approximately 16% lower for Tacrolimus QD than for Tacrolimus BID, although by day 3 onward, the exposure was similar between treatment groups. Tacrolimus 25-35 BH3 interacting domain death agonist Homo sapiens 111-114 22406656-9 2012 There was a good correlation between AUC0-24 and concentration of tacrolimus at 24 hours postdose for both formulations (Tacrolimus QD, r = 0.87; Tacrolimus BID, r = 0.92), and the slope of the line of best fit was similar. Tacrolimus 146-156 BH3 interacting domain death agonist Homo sapiens 157-160 22406656-10 2012 CONCLUSIONS: These results suggest that initiating tacrolimus therapy before transplant reduces the difference in exposure between Tacrolimus QD and Tacrolimus BID. Tacrolimus 51-61 BH3 interacting domain death agonist Homo sapiens 160-163 22406656-10 2012 CONCLUSIONS: These results suggest that initiating tacrolimus therapy before transplant reduces the difference in exposure between Tacrolimus QD and Tacrolimus BID. Tacrolimus 149-159 BH3 interacting domain death agonist Homo sapiens 160-163 22239105-5 2012 Mean (SD) tacrolimus dose was 3.7 (1.7) mg/day during BID and at conversion, and 3.9 (1.8) mg/day at Week 12. Tacrolimus 10-20 BH3 interacting domain death agonist Homo sapiens 54-57 22239105-7 2012 Mean tacrolimus whole blood trough levels were at the lower end of the recommended range during tacrolimus BID and QD; the difference between mean steady-state trough levels was statistically significant (7.5ng/ml vs. 6.5ng/ml; P<0.0001). Tacrolimus 5-15 BH3 interacting domain death agonist Homo sapiens 107-110 21992068-10 2012 Tacrolimus BID to tacrolimus QD conversion is straightforward and does not compromise renal function in stable kidney transplant patients in the short term. Tacrolimus 0-10 BH3 interacting domain death agonist Homo sapiens 11-14 22310593-3 2012 The main aim of this study was to evaluate the effect of conversion from twice-daily tacrolimus (tacrolimus-BID) to once-daily tacrolimus (tacrolimus-OD) on glucose intolerance in stable kidney transplant patients. Tacrolimus 85-95 BH3 interacting domain death agonist Homo sapiens 108-111 22310593-3 2012 The main aim of this study was to evaluate the effect of conversion from twice-daily tacrolimus (tacrolimus-BID) to once-daily tacrolimus (tacrolimus-OD) on glucose intolerance in stable kidney transplant patients. Tacrolimus 97-107 BH3 interacting domain death agonist Homo sapiens 108-111 22310593-3 2012 The main aim of this study was to evaluate the effect of conversion from twice-daily tacrolimus (tacrolimus-BID) to once-daily tacrolimus (tacrolimus-OD) on glucose intolerance in stable kidney transplant patients. Tacrolimus 97-107 BH3 interacting domain death agonist Homo sapiens 108-111 22310593-3 2012 The main aim of this study was to evaluate the effect of conversion from twice-daily tacrolimus (tacrolimus-BID) to once-daily tacrolimus (tacrolimus-OD) on glucose intolerance in stable kidney transplant patients. Tacrolimus 97-107 BH3 interacting domain death agonist Homo sapiens 108-111 22310593-13 2012 CONCLUSION: The results of this study suggests that conversion from tacrolimus-BID to tacrolimus-OD may benefit kidney transplant patients with glucose intolerance because of improved insulin secretion. Tacrolimus 68-78 BH3 interacting domain death agonist Homo sapiens 79-82 21493098-10 2011 CONCLUSIONS: This study provides evidence for successful conversion from tacrolimus BID to QD on a 1:1 (mg/mg) total daily dose basis. Tacrolimus 73-83 BH3 interacting domain death agonist Homo sapiens 84-87 21493098-13 2011 Adverse events were reported by approximately one-tenth of patients receiving tacrolimus BID and a quarter of those who received QD. Tacrolimus 78-88 BH3 interacting domain death agonist Homo sapiens 89-92 21099736-6 2011 All animals received intravenous Tacrolimus (0.025 mg/kg) BID during the course of the study. Tacrolimus 33-43 BH3 interacting domain death agonist Homo sapiens 58-61 21280190-1 2011 Tacrolimus, a cornerstone immunosuppressant, is available as a twice-daily formulation (tacrolimus bid). Tacrolimus 0-10 BH3 interacting domain death agonist Homo sapiens 99-102 21280190-1 2011 Tacrolimus, a cornerstone immunosuppressant, is available as a twice-daily formulation (tacrolimus bid). Tacrolimus 88-98 BH3 interacting domain death agonist Homo sapiens 99-102 21280190-6 2011 Tacrolimus area under the curve (AUC) from 0 to 24 hours (AUC(0-24) ) at equivalent doses was approximately 50% lower for tacrolimus qd than for bid on day 1 (146 versus 264 ng h/mL, respectively), but by day 14 was comparable between treatments (324 and 287 ng h/mL, respectively) with higher tacrolimus qd doses. Tacrolimus 0-10 BH3 interacting domain death agonist Homo sapiens 145-148 21280190-7 2011 There was a strong correlation between AUC(0-24) and concentration at 24 hours for tacrolimus qd and bid (r = 0.92 and r = 0.76, respectively). Tacrolimus 83-93 BH3 interacting domain death agonist Homo sapiens 101-104 19681813-1 2009 Tacrolimus, a cornerstone immunosuppressant, is widely available as a twice-daily formulation (Tacrolimus BID). Tacrolimus 0-10 BH3 interacting domain death agonist Homo sapiens 106-109 20840480-3 2010 Biopsy-proven acute rejection rate at 24 weeks (primary endpoint, per-protocol analysis) was 15.8% for Tacrolimus BID versus 20.4% for Tacrolimus QD (p = 0.182; treatment difference 4.5%, 95% confidence interval-1.8%, 10.9%, just outside the prespecified 10% noninferiority margin). Tacrolimus 103-113 BH3 interacting domain death agonist Homo sapiens 114-117 20840480-4 2010 Kaplan-Meier 12-month patient and graft survival rates were 97.5% and 92.8% for Tacrolimus BID and 96.9% and 91.5% for QD. Tacrolimus 80-90 BH3 interacting domain death agonist Homo sapiens 91-94 20840481-3 2010 The primary endpoint, event rate of biopsy-proven acute rejection (BPAR) at 24 weeks, was 33.7% for tacrolimus BID versus 36.3% for tacrolimus QD (Per-protocol set; p = 0.512; treatment difference 2.6%, 95% confidence interval -7.3%, 12.4%), falling within the predefined 15% noninferiority margin. Tacrolimus 100-110 BH3 interacting domain death agonist Homo sapiens 111-114 20840481-5 2010 Twelve-month patient and graft survival was 90.8% and 85.6% for tacrolimus BID and 89.2% and 85.3% for tacrolimus QD. Tacrolimus 64-74 BH3 interacting domain death agonist Homo sapiens 75-78 19681813-1 2009 Tacrolimus, a cornerstone immunosuppressant, is widely available as a twice-daily formulation (Tacrolimus BID). Tacrolimus 95-105 BH3 interacting domain death agonist Homo sapiens 106-109 19681813-3 2009 This study compared the pharmacokinetics (PK) of tacrolimus in de novo kidney transplant patients treated with Tacrolimus QD or Tacrolimus BID. Tacrolimus 49-59 BH3 interacting domain death agonist Homo sapiens 139-142 19681813-9 2009 Mean AUC(0-24) of tacrolimus on day 1 was approximately 30% lower for Tacrolimus QD than Tacrolimus BID (232 and 361 ng.h/mL, respectively), but was comparable by day 4. Tacrolimus 18-28 BH3 interacting domain death agonist Homo sapiens 100-103 19681813-12 2009 Tacrolimus QD can be administered once daily in the morning on the basis of the same systemic exposure and therapeutic drug monitoring concept as Tacrolimus BID. Tacrolimus 0-10 BH3 interacting domain death agonist Homo sapiens 157-160 30318624-1 2018 Tacrolimus (TAC) is available as a twice-daily capsule (TAC-BID), once-daily capsule (TAC-QD), and once-daily tablet. Tacrolimus 0-10 BH3 interacting domain death agonist Homo sapiens 60-63 32247597-1 2020 BACKGROUND: The aim of the study was to assess bioavailability aspects of tacrolimus formulations during conversion from twice-daily (TAC BID) to once-daily (TAC OD) formulation in 89 stable kidney transplant recipients. Tacrolimus 74-84 BH3 interacting domain death agonist Homo sapiens 138-141 32247597-9 2020 CONCLUSIONS: Conversion from TAC BID to TAC OD is associated with a significant increase in tacrolimus dose during the first 3 months. Tacrolimus 92-102 BH3 interacting domain death agonist Homo sapiens 33-36 12884468-3 2003 These two cases demonstrate a clear-cut therapeutic response of chronic, topical corticosteroid-resistant annular erythema to topical tacrolimus ointment 0.1% BID. Tacrolimus 134-144 BH3 interacting domain death agonist Homo sapiens 159-162 27011912-1 2016 Tacrolimus (Prograf( ), Astellas Pharma Europe Ltd, Staines, United Kingdom; referred to as tacrolimus-BID) is an immunosuppressive agent to prevent and treat allograft rejection in kidney transplant recipients in combination with mycophenolate mofetil, corticosteroids, with or without basiliximab induction. Tacrolimus 0-10 BH3 interacting domain death agonist Homo sapiens 103-106 27011912-1 2016 Tacrolimus (Prograf( ), Astellas Pharma Europe Ltd, Staines, United Kingdom; referred to as tacrolimus-BID) is an immunosuppressive agent to prevent and treat allograft rejection in kidney transplant recipients in combination with mycophenolate mofetil, corticosteroids, with or without basiliximab induction. Tacrolimus 12-19 BH3 interacting domain death agonist Homo sapiens 103-106 27011912-1 2016 Tacrolimus (Prograf( ), Astellas Pharma Europe Ltd, Staines, United Kingdom; referred to as tacrolimus-BID) is an immunosuppressive agent to prevent and treat allograft rejection in kidney transplant recipients in combination with mycophenolate mofetil, corticosteroids, with or without basiliximab induction. Tacrolimus 92-102 BH3 interacting domain death agonist Homo sapiens 103-106 27011912-4 2016 Extended release tacrolimus has similar absorption, distribution, metabolism and excretion to tacrolimus-BID. Tacrolimus 94-104 BH3 interacting domain death agonist Homo sapiens 105-108 27011912-5 2016 Phase I pharmacokinetic trials comparing extended release tacrolimus and tacrolimus-BID have demonstrated a decreased maximum concentration (Cmax) and delayed time to maximum concentration (tmax) with the extended release formulation; however, AUC0-24 was comparable between formulations. Tacrolimus 73-83 BH3 interacting domain death agonist Homo sapiens 84-87 27011912-6 2016 Overall extended release tacrolimus has a very similar safety and efficacy profile to tacrolimus-BID. Tacrolimus 86-96 BH3 interacting domain death agonist Homo sapiens 97-100 26373896-1 2016 The efficacy and safety of tacrolimus twice-a-day (BID) and once-a-day (QD) formulations are similar. Tacrolimus 27-37 BH3 interacting domain death agonist Homo sapiens 51-54